Redeye comments on Smart Eye's rights issue, which was subscribed to more than 100% and was hence su...
Despite a below expectations Q4, at least partly due to increased sickness-related absences, we see ...
Simris’ expanded objective to leverage the acquisition of Cyano Biotech in Q3’22, enter the high-val...
Göteborgsbaserade investmentbolaget Northern CapSek Ventures AB (”CapSek”) portföljbolag Klash Studi...
Redeye provides an update in relation to Enzymatica’s Q4 2022 report.
There will be two alternative IgAN therapies on the US market by the last week of February 2023 as t...
Redeye strengthens its positive view of CombinedX and raises its Base Case and forecasts following a...
Redeye retains its positive view of Speqta despite slightly lowering its forecast and Base Case.
Strong end to the year from NII and market value adjustments Another jumbo dividend yield of 15% for...
Smart High Tech publicerade den 17 februari 2023 bolagets delårsrapport för det fjärde kvartalet 202...
Redeye has a relatively neutral stance on IRRAS’ Q4 report, with sales coming in under and costs abo...
Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA ap...
Redeye provides a research update following Hoylu’s Q4 2022 report.
Redeye updates its estimates and fair value range following Tessin’s Q4 report.
Redeye provides an update on ChromoGenics following the company's Q4 results.
Redeye updates its fair value range following Alelion’s Q4 report, which was weaker than expected.
Redeye was hoping for a stronger finish to 2022 in terms of earnings.
Stockwik delivered a somewhat soft Q4 with a sales growth of 24% y/y, while EBITA declined 2% y/y, b...
Weaker end to 2022 than feared Re-setting growth expectations Still reasons to be optimistic for H2'...
Finding a new level of growth post COVID-19 Impressive profitability in Q4 Low churn confirmed, as e...
